metsera, a clinical-stage biotech company focusing on obesity treatment, has recently gone public and started to attract favorable analyst ratings from wall street firms, showcasing significant potential for share price growth.

metsera is a clinical-stage biotech stock gaining attention due to its connection to the obesity market.

Financial institution initiating coverage of metsera with a buy rating.

Investment firm also initiated coverage of metsera with a buy rating and a high price target.

Major financial institution that has initiated coverage of metsera but did not assign a rating due to its policy.

bank of america analyst who provided a buy rating for metsera.